JDOC uses proprietary research to select healthcare companies considered to be leaders in the space and underappreciated by the market. The fund may be invested in companies across all market capitalizations and located anywhere around the world. Although, the adviser expects a majority of the holdings to be of mid- or large-cap companies located in the US. Companies considered for inclusion are believed to have catalysts that will lead to outperform their peers. For example, such companies may be obtaining regulatory approvals, received favorable clinical outcomes, improving sales growth, or positive research and development momentum. The adviser selects those in which the magnitude and duration of future growth is not yet realized in the stock. The fund may use derivates to manage risk or gain equity exposure. Also, as part of its investment process, the adviser seeks to assess the impact of related ESG factors.
